Cargando…
Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
BACKGROUND: Rapidly progressive (RP) interstitial lung disease (ILD) is a life-threatening complication of juvenile dermatomyositis (JDM); however, it is generally refractory to treatment; to the best of our knowledge, no evidence-based treatment has been established for RP-ILD yet. We present the c...
Autores principales: | Nishi, Kentaro, Ogura, Masao, Tamai, Naotaka, Gima, Naofumi, Ide, Kentaro, Koinuma, Goro, Kamei, Koichi, Ito, Shuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351133/ https://www.ncbi.nlm.nih.gov/pubmed/35927666 http://dx.doi.org/10.1186/s12969-022-00723-5 |
Ejemplares similares
-
Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022) -
Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents
por: Kamei, Koichi, et al.
Publicado: (2022) -
Central venous catheter infection-related glomerulonephritis under long-term parenteral nutrition: a report of two cases
por: Okada, Mari, et al.
Publicado: (2016) -
Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review
por: Ogawa, Yuka, et al.
Publicado: (2017) -
Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)